hyperplasia

(redirected from benign prostatic hyperplasia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

hyperplasia

(hī'pərplā`zhə): see hypertrophyhypertrophy
, enlargement of a tissue or organ of the body resulting from an increase in the size of its cells. Such growth accompanies an increase in the functioning of the tissue. In normal physiology the growth in size of muscles (e.g.
..... Click the link for more information.
.

Hyperplasia

 

an increase in the number of structural elements of tissues or organs. In man and animals, hyperplasia is based on the intensified reproduction of cells and the formation of new structures. Hyperplasia is observed in various types of pathological growth of tissues (chronic productive inflammation and tumor), in regeneration, and in hypertrophy. Hyperplasia often carries with it compensating characters. In plants, it may be a local growth of tissues resulting from mitotic or amitotic cell division. It occurs with infection by destructive or pathogenic organisms, during trauma, and under the influence of growth stimulants, pesticides, and other preparations. The result of hyperplasia is the formation of galls, calluses, and warts.

hyperplasia

[‚hī·pər′plā·zhə]
(medicine)
Increase in cell number causing an increase in the size of a tissue or organ.
References in periodicals archive ?
2010 Update: Guidelines for the management of benign prostatic hyperplasia.
The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.
Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of route of administration and molecule type.
Practice patterns of Canadian urologists in benign prostatic hyperplasia and prostate cancer.
Benign prostatic hyperplasia, or enlarged prostate, is a non-cancerous growth of the prostate tissue that obstructs bladder function causing discomfort and lifestyle complications for afflicted men.
Benign Prostatic Hyperplasia Phase 3 Clinical Trial Pipeline Insights
Interventional therapy is an option to alleviate symptoms for men who fail medical management of benign prostatic hyperplasia, but current options are a trade-off between improvement of patient symptoms and a risk of complications.
Review of key trends in the development of new benign prostatic hyperplasia drugs across the seven major markets.
1 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) - Global 13
4 million prevalent cases of benign prostatic hyperplasia (BPH) in men over age 50 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK); approximately 49% of these cases were symptomatic.
The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Benign Prostatic Hyperplasia.
GlobalData's clinical trial report, "Benign Prostatic Hyperplasia Global Clinical Trials Review, Q2, 2011" provides data on the Benign Prostatic Hyperplasia clinical trial scenario.

Full browser ?